Your WHOOP is now drawing blood

WHOOP launched "Specialized Panels", a $299 blood test service through Quest Diagnostics covering 75–89 biomarkers across five targeted panels, with results integrating into WHOOP's AI coaching layer alongside sleep and strain data — broader than Oura's competing Health Panels (50 biomarkers at $99), though Quest's own privacy policy allows broader third-party data use than HIPAA alone (TechRadar, Apr 16).
Garmin filed a CIRQA Smart Band patent for a screenless wearable tracking "physiological data, bio-signals, and bodily behavior" for recovery and alertness — the device briefly appeared on Garmin's own site (two sizes, two colorways) before being pulled. PCMag estimates a May–June 2026 release; Counterpoint Research projects the screenless fitness band segment will grow 16% in 2026.
Google's screenless Fitbit rival (reported last issue as in development) has been repeatedly confirmed on Steph Curry in public since January 2026; Droid-Life's deep-dive confirms a woven-polyester band significantly thinner than WHOOP MG, with leaked app footage showing live sport-tracking and real-time heart rate absent from the current Fitbit app — suggesting imminent launch.
Oura filed a replaceable battery patent using magnetic contacts to enable cell swaps without discarding the full ring (T3) — no current ring-form wearable offers this, directly targeting the category's primary long-term hardware liability.

WHOOP received an FDA warning letter for a blood pressure feature and now markets "WHOOP Age" alongside AI that recommended testosterone optimization to a test user; Oura has integrated Dexcom glucose data, added a "cardiovascular age" estimate, and proposed a new lower-scrutiny "digital screeners" FDA regulatory category — which WHOOP opposes. The Verge frames both as delivering clinically unvetted AI recommendations at scale.
Neither Oura nor WHOOP has demonstrated reduced hospitalizations, changed clinical outcomes, or meaningful care integration, per Axios. The $10B+ valuations (WHOOP raised at $10.1B last issue) are built on the premise of future healthcare utility, not current evidence.
Dr. Mike Varshavski told Fox News he would "never recommend a consumer-grade device" for tracking a true medical condition, noting that athlete performance gains — like Rory McIlroy's — don't validate clinical-grade use.

Stanford researchers demonstrated noninvasive deep-tissue light delivery using nanoparticles that circulate in blood and emit light when hit by focused ultrasound — no implants or fiber optics required. Published April 13 in Nature Materials, the method currently produces 490nm blue light for optogenetics and photodynamic cancer therapy; other wavelengths are in development, with liver accumulation of ceramic nanoparticles the primary limitation and no human trial timeline.
An NPR science explainer benchmarks what PBM evidence actually supports: androgenetic alopecia and oral mucositis (in chemo/radiation patients) have solid backing, alongside peripheral neuropathy and select wound healing; FDA-authorized indications now include dry AMD and fibromyalgia pain. Critical consumer note: "FDA cleared" on a device label means safety testing only — not efficacy; effective wavelengths are 620–1072nm for skin and 630–800nm for hair loss.

Exercise physiologists François Haman and Kelli McCormick told Chatelaine that hormone disruption claims lack human evidence — cited animal studies used hypothermia-inducing temperatures, not typical plunge conditions, and menstrual cycle phase doesn't meaningfully change cold response. Universal risks (cardiac shock, peripheral nerve damage, impaired muscle function) apply regardless of sex; recommended protocol: 2–3 minutes, no solo submersion, no deeper than waist level.

Under hyperbaric pressure, oxygen dissolves directly into plasma, bypassing hemoglobin's 96–99% saturation ceiling and reaching inflamed or poorly vascularized tissue that standard delivery cannot access, per Endurance Hour. Soft-shell "mild HBOT" units common in wellness centers operate at lower atmospheres than medical-grade chambers, significantly limiting plasma O₂ dissolution and therapeutic effect.

Get Biohacking Therapies & Devices in your inbox